Tatva Chintan Pharma Chem earnings calls.

Tatva Chintan delivered a strong Q3 FY26 with operating revenue of ₹131.3 croreCurrent reported value: ₹131.3 crore. No comparable prior figure is available in the source record., up 53Current 53 crore vs previous available quarter 24 crore.% YoY driven by robust growth in Pharma & Agro intermediates (+86% YoY) and Structure Directing Agents (+65% YoY). EBITDA came in at ₹25.5 croreCurrent ₹25.5 crore vs previous available quarter ₹21.8 crore., reflecting 261% YoY growth as operating leverage kicked in from higher capacity utilization (now ~50% vs ~35% earlier). The management remains constructive on the recovery trajectory, highlighting early signs of stabilization across end-use segments including agrochemicals and automotive. The Dahej plant (₹100 croreCurrent ₹100 crore. Reported change: New facility. capex) is ready for commercial production from mid-February 2026, expected to remove production bottlenecks and improve profitability. New agro intermediates based on photochlorination technology have received repeat orders, validating the innovative technology strategy. The company guided for 20-30% revenue growth in FY26-27, targeting ₹850-900 croreCurrent reported value: ₹850-900 crore. No comparable prior figure is available in the source record. revenue in 2.5-3 years. Key risks include geopolitical uncertainties impacting global trade and pricing pressure in commodity chemicals, though management believes prices have bottomed out.